MXPA05013509A - Polipeptidos de fusion de variante ib alfa de glucoproteina de plaquetas y metodos y uso de los mismos. - Google Patents

Polipeptidos de fusion de variante ib alfa de glucoproteina de plaquetas y metodos y uso de los mismos.

Info

Publication number
MXPA05013509A
MXPA05013509A MXPA05013509A MXPA05013509A MXPA05013509A MX PA05013509 A MXPA05013509 A MX PA05013509A MX PA05013509 A MXPA05013509 A MX PA05013509A MX PA05013509 A MXPA05013509 A MX PA05013509A MX PA05013509 A MXPA05013509 A MX PA05013509A
Authority
MX
Mexico
Prior art keywords
methods
fusion polypeptides
platelet glycoprotein
variant fusion
alpha variant
Prior art date
Application number
MXPA05013509A
Other languages
English (en)
Inventor
Jin Xu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA05013509A publication Critical patent/MXPA05013509A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion proporciona composiciones y metodos para el tratamiento o prevencion de los trastornos vasculares asociados.
MXPA05013509A 2003-06-11 2004-06-14 Polipeptidos de fusion de variante ib alfa de glucoproteina de plaquetas y metodos y uso de los mismos. MXPA05013509A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47752503P 2003-06-11 2003-06-11
PCT/US2004/019057 WO2004111089A2 (en) 2003-06-11 2004-06-14 Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
MXPA05013509A true MXPA05013509A (es) 2006-04-05

Family

ID=33551724

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013509A MXPA05013509A (es) 2003-06-11 2004-06-14 Polipeptidos de fusion de variante ib alfa de glucoproteina de plaquetas y metodos y uso de los mismos.

Country Status (16)

Country Link
US (2) US7727535B2 (es)
EP (2) EP1636266A2 (es)
JP (1) JP2007537710A (es)
KR (1) KR20060022261A (es)
CN (1) CN100436480C (es)
AU (1) AU2004247737B2 (es)
BR (1) BRPI0411289A (es)
CA (1) CA2530972A1 (es)
HK (1) HK1095152A1 (es)
IL (2) IL172337A (es)
MX (1) MXPA05013509A (es)
NO (1) NO20060093L (es)
NZ (1) NZ544165A (es)
RU (1) RU2403262C2 (es)
WO (1) WO2004111089A2 (es)
ZA (1) ZA200510331B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US11535673B2 (en) * 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
DE102007031708A1 (de) * 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
ES2672320T3 (es) 2007-08-23 2018-06-13 Bloodcenter Of Wisconsin, Inc. Métodos y kits para la medida del factor de von Willebrand
JP6004594B2 (ja) * 2011-11-15 2016-10-12 ジ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 可溶性メディエーター
EP2794007A4 (en) * 2011-12-23 2015-11-18 Vasculogics Inc COMPOSITIONS AND METHODS FOR TREATING THROMBOSES AND EXTENDING THE LIFE OF THE STORED THROMBOCYTES
EP2919013B1 (de) 2014-03-11 2016-11-02 Siemens Healthcare Diagnostics Products GmbH Verfahren zur Detektion von Modulatoren der GPIb-Thrombin-Interaktion
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
BR112016030740A2 (pt) 2014-07-01 2018-02-20 Pfizer Inc. diacorpos heterodiméricos biespecíficos e seus usos
CA3086449A1 (en) * 2018-02-20 2019-08-29 Grifols Diagnostic Solutions Inc. Composition comprising recombinant gpiba receptor protein
CN113264995A (zh) * 2021-05-26 2021-08-17 苏州大学 一种血小板GPIbα蛋白相关的抗原表位肽及其应用
WO2023007182A1 (en) * 2021-07-29 2023-02-02 The University Of Birmingham Protein interaction inhibitors
WO2023109903A1 (zh) * 2021-12-15 2023-06-22 上海循曜生物科技有限公司 治疗血小板减少的产品及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340727A (en) 1987-11-17 1994-08-23 The Scripps Research Institute GPIbα fragments and recombinant DNA expression vectors
IL88308A0 (en) * 1987-11-17 1989-06-30 Scripps Clinic Res Peptides that block the binding of von willebrand factor
US4899195A (en) * 1988-01-29 1990-02-06 Ushio Denki Method of exposing a peripheral part of wafer
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5194743A (en) * 1990-04-06 1993-03-16 Nikon Corporation Device for positioning circular semiconductor wafers
JP2874280B2 (ja) * 1990-05-16 1999-03-24 株式会社ニコン 周縁露光装置及び周縁露光方法
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5317097A (en) 1991-10-07 1994-05-31 The Research Foundation Of State University Of New York Mutations in the gene encoding the α chain on platelet glycoprotein IB
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5516964A (en) 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
TW316322B (es) * 1995-10-02 1997-09-21 Ushio Electric Inc
JP3237522B2 (ja) * 1996-02-05 2001-12-10 ウシオ電機株式会社 ウエハ周辺露光方法および装置
JP3735921B2 (ja) 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
ATE417068T1 (de) 1998-04-23 2008-12-15 Ajinomoto Kk Stoff mit antithrombotischer aktivität und verfahren zur bestimmung von glycokallidin
AR035779A1 (es) 2001-02-06 2004-07-14 Genetics Inst Llc Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos

Also Published As

Publication number Publication date
KR20060022261A (ko) 2006-03-09
EP2522677A1 (en) 2012-11-14
WO2004111089A3 (en) 2005-05-12
US20050089888A1 (en) 2005-04-28
RU2006100306A (ru) 2006-06-10
JP2007537710A (ja) 2007-12-27
WO2004111089A2 (en) 2004-12-23
IL172337A (en) 2012-07-31
US7727535B2 (en) 2010-06-01
BRPI0411289A (pt) 2006-08-01
EP1636266A2 (en) 2006-03-22
US20110039780A1 (en) 2011-02-17
CN1823090A (zh) 2006-08-23
RU2403262C2 (ru) 2010-11-10
CA2530972A1 (en) 2004-12-23
NO20060093L (no) 2006-03-01
CN100436480C (zh) 2008-11-26
AU2004247737B2 (en) 2009-04-23
IL220272A0 (en) 2012-07-31
AU2004247737A1 (en) 2004-12-23
ZA200510331B (en) 2007-03-28
NZ544165A (en) 2008-12-24
HK1095152A1 (en) 2007-04-27

Similar Documents

Publication Publication Date Title
NO20060093L (no) Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav
IL245462A0 (en) Antagonists of human origin against cmet
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
NO20034056D0 (no) Proliferative sykdommer
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
WO2003103571A3 (en) VACCINES AGAINST FLAVIVIRUSES
HK1046912A1 (en) Substituted sapogenins and their use
EP1399160A4 (en) NR2B RECEPTOR ANTAGONISTS FOR TREATING OR PREVENTING MIGRAINE
TNSN06202A1 (en) Anticorps agonistes inti-trkc et procedes qui les utilisent
DE60128701D1 (en) Claudin polypeptide
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
WO2002063003A3 (en) Platlet glycoprotein ib alpha fusion polypeptides and methods of use thereof
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
AU2003251729A8 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
MXPA03008039A (es) Polipeptidos de serpina humanos.
ATE405577T1 (de) Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2003100001A3 (en) Claudin polypeptides, polynucleotides, and methods of making and use thereof
EP1381682A4 (en) MODULATORS OF LEUCOCYTE ACTIVATION, COMPOSITIONS AND METHODS OF USE
EP1602726A3 (en) Human tachykinin-related splice variants and compositions thereof
DE602004024844D1 (de) Zusammensetzung für die Wiederherstellung von Knochen und umliegendem Gewebe

Legal Events

Date Code Title Description
FG Grant or registration